Here’s Why You Can’t Trust CannTrust Stock

In This Article:

If you’ve followed my work over the past year, you know that I’m a strong supporter of marijuana stocks. While the viability of individual names varies, overall, the lack of a defined upside excites me. In other words, the cannabis market could be the most transformative of our generation. Or it could crash and burn. For CannTrust Holdings (NYSE:CTST) and CannTrust stock, I’m referring to the latter.

Source: Shutterstock

In short, CTST stock could be the first of the major New York Stock Exchange-traded cannabis companies to implode. Granted, I’m not breaking new ground here. Since the beginning of July of this year, shares have cratered over 68%. It’s a good thing that Stockcharts.com defaults to a logarithmic scale for their charts; otherwise, it’d be hard to fit that magnitude of a drop in nominal unit-based scale.

Initially, the troubles for CannTrust stock began when Health Canada, the namesake country’s federal health agency, discovered a shocking scandal: CannTrust was illegally growing cannabis. But it wasn’t just the infraction against clearly defined rules and protocol that hemorrhaged CTST stock. Instead, it was the violation’s deliberate nature.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

CannTrust employees, with the knowledge of executive leadership, created illegal grow rooms hidden behind false walls. Clearly, management premeditated their actions. Thus, it was no surprise that the company fired former CEO Peter Aceto with cause.

If that wasn’t bad enough for CannTrust stock, we have another scandal: black market cannabis seeds allegedly got mixed into CannTrust’s inventory.

While it’s not as dramatic of a headline as the hidden grow rooms, this latest controversy could spell big trouble for CTST stock. Thus, I wouldn’t even gamble on the name.

CannTrust Stock Has Zero Credibility

Since its inception, virtually all marijuana companies sought one attribute: credibility.

During the early stages of the green market, companies attempted to convince investors, potential partners and financial institutions that their underlying business was realistically viable. Right now, these same firms are attempting to show that they can convert some of these storylines into actual results.

However, it’s been a trying time. Established leaders, such as Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC), Tilray (NASDAQ:TLRY) and most recently Aurora Cannabis (NYSE:ACB) have attempted to do this conversion through their earnings results. So far, they’ve failed spectacularly.